.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,368,469

« Back to Dashboard
Patent 7,368,469 protects ALTACE and is included in two NDAs.

This patent has forty-three patent family members in thirty-one countries.

Summary for Patent: 7,368,469

Title:Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
Abstract:Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.
Inventor(s): Scholkens; Bernward (Kelkheim, DE), Bender; Norbert (Hofheim, DE), Rangoonwala; Badrudin (Hofheim, DE), Dagenais; Gilles (St.-Nicholas, CA), Gerstein; Hertzel (Hamilton, CA), Yusuf; Salim (Carlisle, CA)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt, DE)
Application Number:11/490,061
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 144th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
King Pharms
ALTACE
ramipril
CAPSULE;ORAL019901-001Jan 28, 1991RXNo7,368,469► subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pharms
ALTACE
ramipril
CAPSULE;ORAL019901-002Jan 28, 1991RXNo7,368,469► subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pharms
ALTACE
ramipril
CAPSULE;ORAL019901-003Jan 28, 1991RXNo7,368,469► subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,368,469

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey200200515► subscribe
Slovakia2692002► subscribe
Slovenia1216038► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc